Ultima Genomics wins sequencing award for Singapore's NPM Phase III
Ultima Genomics says its UG200 Sequencing Platform has been selected for SG-INSIGHT, a cohort in Phase III of Singapore's National Precision Medicine (NPM) program. The company describes it as its first major win to support a national-scale clinical whole genome sequencing initiative.
- Ultima's UG200 Sequencing Platform was selected for SG-INSIGHT, a cohort in Phase III of Singapore's National Precision Medicine program.
- NPM Phase III expands to about 450,000 individuals, nearly one in 10 Singapore residents, and includes patients from three public healthcare clusters.
- Ultima works with Lucence, which leads the consortium, and QIAGEN, which supports sample preparation and automation.
- Ultima calls it its first major win for a national-scale clinical whole genome sequencing initiative.
- Pangenome-aware WGS analysis is expected by year-end 2026, according to the company.
What was awarded
According to Ultima Genomics, the UG200 platform will be used for SG-INSIGHT, part of a national initiative focused on bringing genomics into clinical workflows and healthcare delivery. Precision Health Research, Singapore (PRECISE) is the central coordinating office for the NPM program.
Ultima says the selection followed an extensive evaluation process. The company states that it and its consortium partners addressed quality, clinical readiness, pricing and innovation, using the UG200 system, Solaris 2.0 chemistry and bioinformatics analytics. Solaris 2.0 chemistry and the UG200 platform were launched in February 2026, according to the company.
Ultima is working with two partners. Lucence, a Singapore-based clinical lab, leads the consortium. QIAGEN, which Ultima describes as a global leader in Sample to Insight solutions, is the other partner.
Scale of NPM Phase III
Phase III widens the program to about 450,000 individuals, which the release describes as nearly one in 10 Singapore residents. Phase II, which sequenced 100,000 Singaporeans according to PRECISE, focused on healthy individuals. Phase III instead includes patients with a wide range of health conditions from Singapore's three public healthcare clusters: NHG Health, National University Health System (NUHS) and SingHealth.
The phase is intended to generate evidence to support the safe and effective rollout of genetic screening and the future integration of genomics into public healthcare.
Division of work in the consortium
Under the collaboration, the roles are split as follows:
- Lucence: end-to-end clinical program management and local operational leadership.
- QIAGEN: sample preparation and automation workflows.
- Ultima: sequencing and genomic analysis capabilities designed to enable high-quality, scalable, clinical-grade whole-genome sequencing.
The consortium aims to support the execution of NPM Phase III and to establish a model for future national genomics initiatives.
What it means for Ultima and the market
Gilad Almogy, Chief Executive Officer of Ultima Genomics, called the award "an important milestone for Ultima Genomics" that shows advancements that "unlock whole genome sequencing for clinical applications at scale, at low cost, and with high-quality data." He said the UG200 can enable customers and partners to support cost-sensitive initiatives.
The company says the win strengthens its presence in the Asia-Pacific region. It also expects SG-INSIGHT to serve as a key reference program as governments, healthcare providers and research institutions explore broader adoption of precision medicine.
Ultima also says it continues to develop its offering for population-scale clinical sequencing. It has recently launched paired-end sequencing and is developing pangenome-aware whole genome sequencing analysis, which it expects to be available by year-end 2026. The release includes forward-looking statements and notes that outcomes depend on factors such as program timelines, clinical validation and operational execution.
